A short-sell attack sends Ginkgo’s share price spinning, underscoring investors’ concerns over synbio field

Ginkgo Bioworks, a synthetic biology unicorn that has captured investors’ imaginations and trades under Genentech’s hallowed  old $DNA ticker, took a big blow Wednesday after a short seller claimed the company represents “a Frankenstein mash-up of the worst frauds of the last 20 years.” Scorpion Capital, a hedge fund most…

...

Click to view original post